MX2016005869A - Inhibidor de beta-lactamasa cristalina. - Google Patents

Inhibidor de beta-lactamasa cristalina.

Info

Publication number
MX2016005869A
MX2016005869A MX2016005869A MX2016005869A MX2016005869A MX 2016005869 A MX2016005869 A MX 2016005869A MX 2016005869 A MX2016005869 A MX 2016005869A MX 2016005869 A MX2016005869 A MX 2016005869A MX 2016005869 A MX2016005869 A MX 2016005869A
Authority
MX
Mexico
Prior art keywords
lactamase inhibitor
crystalline beta
formula
crystalline
beta
Prior art date
Application number
MX2016005869A
Other languages
English (en)
Spanish (es)
Inventor
Lamonica Alessandro
Forzatti Marco
Biondi Stefano
Original Assignee
Allecra Therapeutics Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49818360&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016005869(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allecra Therapeutics Sas filed Critical Allecra Therapeutics Sas
Publication of MX2016005869A publication Critical patent/MX2016005869A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/86Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with only atoms other than nitrogen atoms directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D499/00Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/87Compounds being unsubstituted in position 3 or with substituents other than only two methyl radicals attached in position 3, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2016005869A 2013-11-08 2014-11-07 Inhibidor de beta-lactamasa cristalina. MX2016005869A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1319776.9A GB201319776D0 (en) 2013-11-08 2013-11-08 Compound
GBGB1408643.3A GB201408643D0 (en) 2013-11-08 2014-05-15 Compound
PCT/EP2014/074108 WO2015067787A1 (en) 2013-11-08 2014-11-07 Crystalline beta-lactamase inhibitor

Publications (1)

Publication Number Publication Date
MX2016005869A true MX2016005869A (es) 2017-01-05

Family

ID=49818360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005869A MX2016005869A (es) 2013-11-08 2014-11-07 Inhibidor de beta-lactamasa cristalina.

Country Status (14)

Country Link
US (2) US20160289245A1 (enExample)
EP (1) EP3066103A1 (enExample)
JP (2) JP7045795B2 (enExample)
KR (1) KR20160081964A (enExample)
CN (1) CN105873935B (enExample)
AU (1) AU2014345507B2 (enExample)
CA (1) CA2929199C (enExample)
CL (1) CL2016001097A1 (enExample)
EA (1) EA031348B1 (enExample)
GB (2) GB201319776D0 (enExample)
IL (1) IL245386A0 (enExample)
MX (1) MX2016005869A (enExample)
PE (1) PE20160890A1 (enExample)
WO (1) WO2015067787A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201319776D0 (en) * 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
WO2026086730A1 (zh) * 2024-10-21 2026-04-30 齐鲁制药有限公司 恩美他唑巴坦的晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562073A (en) * 1982-12-24 1985-12-31 Taiho Pharmaceutical Company Limited Penicillin derivatives
US6156745A (en) * 1997-12-29 2000-12-05 Research Corporation Technologies, Inc. 2β-substituted-6-alkylidene penicillanic acid derivatives as β-lactamase inhibitors
US7273935B2 (en) * 2003-08-21 2007-09-25 Orchid Chemicals & Pharmaceuticals, Ltd. Process for the preparation of 3-methylcepham derivatives
US7417143B2 (en) * 2004-04-07 2008-08-26 Orchid Chemicals & Pharmaceuticals Limited Process for the preparation of Tazobactam in pure form
US7687488B2 (en) * 2006-07-12 2010-03-30 Orchid Chemicals & Pharmaceuticals Ltd. 2-substituted methyl penam derivatives
NZ610247A (en) * 2010-11-25 2014-09-26 Allecra Therapeutics Gmbh Β-lactamase inhibitors and their use
EP2847205A4 (en) * 2012-05-07 2016-01-20 Univ California NOVEL OXYSTEROL ANALOGUE OXY149 FOR THE INDUCTION OF OSTEOGENESIS AND HEDGEHOG SIGNAL PATH AND THE INHIBITION OF ADIPOGENESIS
US9683009B2 (en) * 2013-05-02 2017-06-20 The Regents Of The University Of California Bone-selective osteogenic oxysterol-bone targeting agents
GB201319776D0 (en) 2013-11-08 2013-12-25 Allecra Therapeutics Sas Compound
GB201408649D0 (en) * 2014-05-15 2014-07-02 Allecra Therapeutics Sas Method
KR20170101940A (ko) * 2014-12-09 2017-09-06 워쏘우 오르쏘페딕 인코포레이티드 스테롤 관련 화합물 및 방법

Also Published As

Publication number Publication date
EP3066103A1 (en) 2016-09-14
GB201319776D0 (en) 2013-12-25
CA2929199A1 (en) 2015-05-14
GB201408643D0 (en) 2014-07-02
US20190071456A1 (en) 2019-03-07
JP7045795B2 (ja) 2022-04-01
CN105873935B (zh) 2019-03-19
CA2929199C (en) 2023-01-03
CL2016001097A1 (es) 2016-12-02
AU2014345507A1 (en) 2016-05-19
WO2015067787A1 (en) 2015-05-14
JP2016535054A (ja) 2016-11-10
US20160289245A1 (en) 2016-10-06
AU2014345507B2 (en) 2018-11-22
JP2021102642A (ja) 2021-07-15
EA031348B1 (ru) 2018-12-28
JP7346485B2 (ja) 2023-09-19
KR20160081964A (ko) 2016-07-08
PE20160890A1 (es) 2016-08-25
CN105873935A (zh) 2016-08-17
US11124526B2 (en) 2021-09-21
IL245386A0 (en) 2016-06-30
EA201690963A1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
NZ713621A (en) Compounds and methods of treating infections
NZ713615A (en) Methods for treating bacterial infections
WO2015003816A3 (en) Cystobactamides
NZ617104A (en) Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
MX363678B (es) Terapia de combinación que comprende oxazolidinona-quinolonas para usarse en el tratamiento de infecciones bacterianas.
MX348974B (es) Derivados 1,6 - diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX338610B (es) Composiciones farmaceuticas que comprenden sulbactam e inhibidor de beta-lactamasa.
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
BR112015013123A2 (pt) inibidores de beta-lactamase
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX2013005994A (es) Monobactamas.
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
MX2017012545A (es) Compuestos heterociclicos y su uso en la prevencion o tratamiento de las infecciones bacterianas.
MX359104B (es) Derivados de polimixina y su uso en terapia de combinacion junto con diferentes antibioticos.
MX2016009248A (es) Compuestos que contienen nitrogeno y su uso como agentes antibacterianos.
PH12015501588B1 (en) Compounds and methods for treating bacterial infections
NZ628927A (en) Compounds and methods for treating candidiasis and aspergillus infections
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
HK1222339A1 (zh) 金属-β-内酰胺酶的抑制剂
MX2016004509A (es) Compuestos que contienen nitrogeno y su uso.
MX364443B (es) Agentes antimicrobianos.
PH12014501239A1 (en) Thymol and totarol antibacterial composition
EA201690963A1 (ru) КРИСТАЛЛИЧЕСКИЙ ИНГИБИТОР β-ЛАКТАМАЗЫ
HK1228402A1 (en) Crystalline beta-lactamase inhibitor